Initial Therapeutics

Initial Therapeutics

生物技术研究

South San Francisco,California 2,144 位关注者

Preventing pathogenic protein synthesis

关于我们

Initial Therapeutics is discovering and developing a new class of small-molecule medicines designed to halt pathogenic protein formation in the earliest stages. Initial’s approach is unique and starkly differentiated from protein degradation and other interventions that recognize and tackle proteins only after they have been fully formed.

网站
https://initialtx.com/
所属行业
生物技术研究
规模
11-50 人
总部
South San Francisco,California
类型
私人持股
创立
2020
领域
biotech、biotechnology、life sciences、pharmaceuticals、drug discovery和drug development

地点

  • 主要

    285 E Grand Ave

    US,California,South San Francisco,94080

    获取路线

Initial Therapeutics员工

动态

相似主页

查看职位

融资

Initial Therapeutics 共 2 轮

上一轮

A 轮

US$75,000,000.00

Crunchbase 上查看更多信息